Susan Berry is a Medical Compliance Manager for Boehringer-Ingelheim and has spent over 20 years in the pharmaceutical industry in various capacities. She is currently leading two global submission projects focusing on facilitating successful regulatory inspections in the United States, Europe, Japan, and China; has contributed to the development of global training programs for different aspects of the Quality Management System; and is leading global projects focusing on gaining regulatory approval for new drug indications. Previously Susan has worked for Affinium Pharmaceuticals helping to synthesize a novel compound that moved into pre-clinical and then Phase 1 clinical development. Before that she worked for Shire Biochem as a Medicinal Synthetic Chemist developing novel compounds as potential antivirals.

Susan holds a Masters in Clinical Research from George Washington University and an M.Phil. in Natural Product Chemistry from the University of the West Indies, Mona Campus.